Fallopian Tube Cancer Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Cells in the body divide and grow to replace damaged and old cells. Cell growth is highly regulated and when sufficient amount of cells are produced to replace the old ones, the division of normal cells is stopped. Regulation error in the cell division process can cause cells to continually divide in an uncontrollable manner, which leads to the development of tumor. Fallopian tubes are also known as oviducts, which are a pair of narrow tubes that transport ova (eggs) to the uterus. Abnormal growth of malignant cells in one or both fallopian tubes in women can cause fallopian tube cancer. Majority of fallopian tube cancer are of papillary serous adenocarcinomas type, the other two types of fallopian tube cancer are very rare such as sarcoma, which affects the muscular part of the fallopian tube and transitional cell found in the fallopian tube lining, and metastasis that spreads cancer cells to other parts of the body. The symptoms of ovarian cancer are similar to that of fallopian tube cancer, which include abdominal pain, watery discharge that may contain blood, vaginal bleeding, and swollen abdomen. Tests for diagnosis of fallopian tube cancer include CA125 blood test, pelvic exam, ultrasound, and CT scan. Some of the recommended treatment options for fallopian tube cancer are open surgery treatment, which involves the removal of the uterus through an incision in the abdomen and chemotherapy treatment, using drugs to kill cancer cells, which may be prescribed pre- and post-surgery.

Click to Continue Reading on Fallopian Tube Cancer Market

Fallopian Tube Cancer Market Dynamics

Increasing development of treatments is expected to boost growth of the fallopian tube cancer market. For instance, In 2018 Rucaparib, a poly ADP-ribose polymerase (PARP) inhibitor, developed by Clovis Oncology Inc. received FDA approval for the maintenance treatment of recurrent fallopian tube cancer, ovarian cancer or primary peritoneal cancer. Moreover, increasing prevalence of cancer-related diseases and genetic disorders are factors responsible for fallopian tube cancer market growth. According to 2018 statistics by the Foundation for Women’s Cancer, around 32,120 women are projected to die from gynecologic cancer diseases and 110,070 women are projected to be diagnosed with a gynecologic cancer in 2018. According to the American Society of Clinical Oncology, in the U.S., around 22,240 cases of ovarian cancer were diagnosed in 2017.

Major challenges faced by the fallopian tube cancer market players include high treatment costs, and side effects associated with the chemotherapy treatment such as fatigue, hair loss, and nausea are expected to hinder the market growth. For instance, according to published article in Journal of the National Comprehensive Network 2016, the mean total payment per patient in the initial treatment period of ovarian cancer was US$ 65,908.

Fallopian Tube Cancer Market – Regional Insights

On the basis of geography, the global fallopian tube cancer market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America fallopian tube cancer market holds a dominant position on account of increasing number of fallopian tube cancer cases and high R&D investment from government organization for the prevention of cancer-related diseases in the region. For instance, according to the National Cancer Institute in 2016 fiscal year report, around US$ 95,587,126 was funded for ovarian cancer research alone. Asia Pacific is considered as the emerging market in the global fallopian tube cancer market. Rising incidence of fallopian cancer in Asia Pacific is expected to be a major factor of growth for this region, supported by growing awareness among the population. For instance, according to a published article in 2015 Chinese Journal of Cancer Research, showed around 45,223 new ovary cancer cases, accounting for 3.11% of all new female cancer cases in China in 2011.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1826

Fallopian Tube Cancer Market – Competitive Landscape

Major players operating in the global fallopian tube cancer market include Roche, Tesaro, Clovis Oncology, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, and F. Hoffmann-La Roche Ltd. Major players are engaged in developing advanced products for fallopian tube cancer treatment and are focusing on collaborations, in order to retain their foothold in the global market. For Instance, in 2017, Merck & Co., Inc. and AstraZeneca enrolled a global strategic oncology collaboration to co-commercialize and co-develop AstraZeneca’s Lynparza for multiple cancer types. Lynparza, an innovative, top-tier oral poly ADP ribose polymerase (PARP) inhibitor, is approved in 2014 for BRCA1 gene mutated ovarian cancer in multiple line of treatment.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Medical Radiation Detection, Monitoring, and Safety Market: Drivers, Regional Analysis, And Competitive Landscape 2026

Radiation power is used in various fields such as industries, agriculture, and medicine to benefit humankind. It is widely being used in modern medical treatments, especially for the treatment of cancer, as radiation helps in weakening and destroying particular cancer cells. Modern medicine uses radiation power to obtain diagnostic information about a patient’s specific organ for treatment. Medical imaging helps in diagnosing and detection of diseases at early stages. For instance, exploratory cardiac catheterization is replaced with CT scan for the detection of polyp in the body, which can turn cancerous if it is not detected at the early stage. Medical radiation detection, monitoring, and safety market is segmented into detector type, monitoring products, and safety products. Various types of detectors include solid-state detectors, liquid filled detectors, and scintillators. Solid-state detectors, which provides good accuracy and reproducibility, are used to perform in vivo dosimetry and quality control for both radiotherapy and radiology.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1802

Medical Radiation Detection, Monitoring, and Safety Market: Drivers

Increasing use of radiation therapy for treatment and diagnosis purposes is expected to fuel growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the National Academics of Sciences Engineering and Medicine in 2016, over 400 million diagnostic examinations and around150 million dental X-ray examinations were performed in the 2015. Increasing prevalence of cancer, rising awareness about use of radiation therapy to treat diseases, and favorable reimbursement policies are other factors that drive growth of medical radiation detection, monitoring, and safety market. According to a study conducted by the U.S. Department of Health & Human Services in 2016, over 80% people in the U.S. have some form of medical insurance. Mergers and acquisitions adopted by major players are also expected to drive growth of medical radiation detection, monitoring, and safety market. For instance, in 2014, Elekta, a Sweden-based company acquired Medical Resonant Inc., a Canada based company. Through this acquisition, Elekta added new solutions for image guidance and R&D resources in the field of oncology imaging to their product portfolio. Moreover, innovations in the field of radiation therapy is expected to boost growth of medical radiation detection, monitoring, and safety market. For instance, in 2017, QFix, a U.S.-based company launched Access 360 G2 and Access Prone G2, a radiotherapy positioning technology for precise treatment of breast cancer. These devices reduce radiation dose to a healthy tissue while improving patient comfort.

However, lack of skilled technicians to use radiation therapy devices and high cost of radiation therapy devices are factors that hamper growth of the market.

Medical Radiation Detection, Monitoring, and Safety Market: Regional Analysis

North America is expected to witness significant growth in the medical radiation detection, monitoring, and safety market over the forecast period due to new innovations in radiation therapy in the region. For instance, in April 2018, Varian Medical Systems, a U.S.-based company launched 4.0 velocity cancer imaging software with selective internal radiation therapy dosimetry analysis. This software includes Rapidsphere, a module used for Selective Internal Radiation Therapy (SIRT) dosimetry analysis. Rapidsphere provides the ability to understand tumor response and normal tissue toxicity for individual patients receiving SIRT.

Asia Pacific is expected to witness significant growth in the medical radiation detection, monitoring, and safety market over the forecast period due to reimbursement policies made by the government. For instance, the Central Government Health Scheme in India has taken initiative to reimburse medical expenses within 6 months of treatment of diseases such as cancer and cardiovascular diseases. Furthermore, Europe is expected to witness growth in the market due to high prevalence of cancer. According to a study conducted by the European Cancer Organisation, in 2017, over 1.7 billion people were diagnosed with cancer, out of which around 20% of the people died due to late treatment and diagnosis.

Click To Continue Reading on Medical Radiation Detection, Monitoring, and Safety Market

Medical Radiation Detection, Monitoring, and Safety Market: Competitive Landscape

Key players operating in the medical radiation detection, monitoring, and safety market include Thermo Fisher Scientific Inc., Canberra Industries Inc., Bar-Ray products Inc., Protech Radiation Safety, ProtecX, Landauer Inc., Mirion Technologies Inc., Amtech Inc., and Biodex Medical Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Peptide Therapeutics Market to surpass US$ 45.0 billion by 2026: CMI

The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Peptide therapeutics have wide range of applications in medicine and biotechnology and therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1) agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative market growth, as Victoza from Novo Nordisk, is the most prominent member of the class, reaching blockbuster status. Moreover, main area currently driving the growth of peptide therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore, peptide therapeutics are in clinical testing for infectious diseases and inflammation.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1837

Key players in the peptide therapeutic market are engaged in expanding market share through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity (dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA), approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Peptide therapeutics market is projected to witness lucrative growth over the forecast period, owing to the various in-organic growth strategies implemented by key manufacturing players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.

Furthermore, in September 2015, PeptiDream Inc. developed a multi-target discovery and optimization collaboration with Sanofi S.A. Under this agreement, PeptiDream will use their proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi S.A. Furthermore, Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.

Browse 26 Market Data Tables and 45 Figures spread through 189 Pages and in-depth TOC on "Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others) - Global Forecast to 2026"

To know the latest trends and insights related to peptide therapeutics market, click the link below: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837

In December 2017, Entrega collaborated with Eli Lilly and Company to make advancement in Entrega’s proprietary peptide delivery technology. Under the agreement, Entrega will receive the US$ 5 million in equity and research in funding from Eli Lilly to investigate the application of Entrega’s peptide delivery technology to certain Lilly products and their therapeutic candidates.

Key takeaways of the Peptide Therapeutics Market:

• The global peptide therapeutics market is expected to expand at a CAGR of 9.1% during the forecast period (2018 – 2026), owing to increasing technological advancement in peptide therapeutics by various key players.
• Among type segment, branded therapeutic peptide is expected to witness significant growth in peptide therapeutics market, owing to increasing investment by various key manufacturers in research and development (R&D) for the development of branded or innovative peptide drugs and high prescription rate.
• Cancer holds major market share in application segment due to increasing prevalence and incidence among global population. In addition, increasing adoption of peptide therapeutics in cancer treatment, growing awareness among the patients and healthcare professionals regarding adverse effects of chemotherapy and growing need towards alternative therapeutics such as peptide-based drugs, will further drive the cancer segment of peptide therapeutics market.
• Parenteral administration holds largest market share in route of administration segment, owing to easy and increased absorption of peptide drugs into the patient’s body. According to the Drug Discovery Today, January 2015 data findings, majority (75%) of the peptide drugs are administrated by parenteral route.
• Some of the major players operating in global peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., and Amgen Inc.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Endocrine Testing Market - Latest Advancements & Market Outlook 2018 to 2026

The Global Endocrine Testing Market, by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S, and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories, and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2.95 billion in 2017 and is projected to exhibit a CAGR of 4.9% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Browse 45 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on “Endocrine Testing Market - by Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Progesterone, Human chorionic gonadotropin, Prolactin, Cortisol DHEA-S and Others), by Diagnostic Technology (Immunoassay, Tandem Mass Spectroscopy, Monoclonal and Polyclonal Antibody, Sensor Technologies, Clinical Chemistry, and Others), by End User (Hospitals, Diagnostic Laboratories and others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global forecast to 2026”

To know the latest trends and insights prevalent in the endocrine testing market, click the link below: https://www.coherentmarketinsights.com/market-insight/endocrine-testing-market-1755

Endocrine testing allows profiling of blood concentration of the various endocrine hormone. Over secretion and under secretion of endocrinal hormones results in to development of endocrinal disease. Various endocrinal disease such as hypothyroidism, hyperthyroidism, infertility, polycystic ovarian syndrome, hypo/hyperadrenocorticism, hypogonadism, diabetes, Multiple endocrine neoplasia I and II, Cushing’s disease, Gigantism (acromegaly) and other growth hormone problem and precocious puberty( Early Puberty). Endocrine diseases are caused due to various reasons such as problem in endocrine feedback system, disease condition, and failure of stimulation of glands to release hormones, tumor of an endocrine gland, genetic disorders, infection and physical trauma to an endocrine gland. Increasing prevalence of these disease especially hypothyroidism, infertility, and diabetes are expected to drive growth of the global endocrinal testing market. According to study published by Centre for Disease Control and Prevention (CDC), in 2017, around 100 million (30.3 million diabetes and 84.1 million prediabetes) U.S. adults were suffering from diabetes or prediabetes condition. According to American Thyroid Association, 2017, around 12% of U.S. adults are estimated to develop thyroid disease in their lifetime. Postmenopausal osteoporosis caused due to reduced estrogen production after menopause leading to low bone mineral density and increased risk for fracture risks. It is estimated that osteoporosis affects around 10 million American adults annually, 34 million people are at high risk of it due to low bone mass, according to study published by BMC Endocrine Disorder in February 2018.

Key players are undergoing strategic mergers, acquisitions, and collaborations in order to maintain leading position in market and to tap the new market. In August 2017, North West London Pathology under National Health Service Trust and Abbott Laboratories signed contract worth US$ 252 million under which Abbott Laboratories will supply all analytical equipment and consumables, this contract would manage 26 million tests annually. In 2017, Abbott Laboratories received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. In April 2018, Beckman Coulter launched its Access Sensitive Estradiol assay in the U.S. market, also made available its assay in the most of global markets. This test accurately detects estradiol levels in women, children, and men using low sample. Company also launched Anti-Müllerian Hormone (AMH) assay in 2017, which helps in clinical management of women suffering from infertility. In 2016, company received FDA clearance and commercially launched new Access TSH (3rd IS) assay.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1755

Key Takeaways of the Endocrine Testing Market:

• The global endocrine testing market is expected to exhibit a CAGR of 4.9% over the forecast period, owing to increasing prevalence of endocrine disease and need for their early diagnosis.
• Among test type, thyroid test segment is expected to hold a dominant position in market during the forecast period due to increasing number of thyroid disorders and its high prevalence. Thyroid test would be followed by fertility related hormone testing (FSH, Progesterone etc.) due to high incidence if infertility throughout globe. Amongst diagnostic technology segment, tandem mass spectroscopy would gain maximum share due to high accuracy and short time to detect the analyte in sample, amongst end user hospitals would prevail over other end user.
• North America region is expected to hold dominant position in the global endocrine testing market, followed by Europe and Asia Pacific. The U.S. has high prevalence of endocrine disease such as hypo/hyperthyroidism. For instance, According to American Thyroid Association, in 2017, around 60% of people suffering from thyroid disease are unaware of their disease. Europe region is expected to witness growth in endocrine testing market, owing to increasing number of population age 65 and above. According to European statistics 2017, around 19% of European population was 65 and above in 2016. Emerging economies from Asia Pacific region are expected to present potential opportunity as this region is facing increasing number in endocrine disorder.
• Key players operating in the endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc., Siemens Healthineers, bioMérieux SA, Agilent Technologies, Bi-Rad Laboratories, AB Sciex, F-Hoffmann La Roche AG, Quest Diagnostics, and others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Non-Surgical Skin Tightening Market – Dynamics, Regional Insights, Competitive Landscape, and Forecast 2026

The recent past has witnessed increasing use of non-invasive skin tightening procedures instead of conventional plastic surgeries. This is owing to increasing awareness regarding non-invasive procedures. Increasing number of people are focusing on one’s aesthetic appeal and this has led to increasing demand for such non-surgical procedures for skin tightening. These procedures aid in reducing wrinkles and improve the texture of the skin, which is used by individuals. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, it was estimated that over 11 million aesthetic procedures were performed by board?certified specialists, of which 16.5% were surgical procedures and 83.5% were non?surgical procedures. Several types of products are available in the market such as ultrasound devices, laser-based devices, and RF devices for conducting various non-surgical skin tightening procedures

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/non-surgical-skin-tightening-market-1776

Non-Surgical Skin Tightening Market – Dynamics

Skin tightening procedures are increasing gaining popularity, especially non-invasive procedures that aid in improving skin laxity. In order to improve one’s aesthetics, people for opting for these procedures. This is a major factor for growth of the market. Moreover, dermatologists are also recommending non-surgical treatment for skin tightening than of invasive procedures. Furthermore, lower cost of these procedures in comparison to invasion surgeries, is another factor for high adoption of these procedures and this is expected to support growth of the market. For instance, according to 2016 American Society of Plastic Surgeons (ASPS) report a normal invasive cosmetic surgery procedure costs about US$ 3,000 to US$ 5,000 each, whereas minimally invasive cosmetic procedures cost around US$ 300 to US$ 650 each. Another factor aiding in growth of the market is increasing approvals for advanced products such as laser products for skin tightening. For instance, in 2015, aesthetic laser systems manufacturer, DEKA Medical, received FDA clearance for its Synchro laser systems.

However, stringent regulations for aesthetic procedures, and high health risk sue to exposure to radiations are expected to hamper growth of the market. For instance, according to a published report in 2011 International Agency for Research on Cancer (IARC) showed the cancer risks involved with use of RF devices. Moreover, repeated treatment is required to maintain the skin and its texture. Therefore, patients have to invest high capital for these repetitive treatments. This could also reduce adoption of such non-surgical procedures thereby, restraining the market growth.

Non-Surgical Skin Tightening Market – Regional Insights

On the basis of region, the global non-surgical skin tightening market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America holds the dominant position in market, owing to increasing awareness of people in the region about one’s aesthetic appeal. Moreover, presence of major market players like Sciton, Inc. and Cynosure Inc. in this region especially in the U.S., is also a major factor accelerating growth of non-surgical skin tightening market size in this region. Furthermore, increasing number of players are launching advanced products in the region for skin tightening. For instance, in 2018, NuFace launched first-ever, FDA-cleared, microcurrent skin toning device, NuBODY, for smoothing of dimpled and uneven skin on the body.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1776

Non-Surgical Skin Tightening Market – Taxonomy

On the basis of product type, the global non-surgical skin tightening market is segmented into:

• Laser-based Devices
• Ultrasound Devices
• RF Devices
• Others

On the basis of end users, the global non-surgical skin tightening market is segmented into:

• Dermatology Clinics
• Beauty Clinics

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Glaucoma Therapeutics Market Clinical Review, Drug Descriptions, Analysis and Synthesis 2026

Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/ongoing-insight/toc/1675

Glaucoma Therapeutics Market Drivers

Increasing number of patients with glaucoma and increasing incidences of blindness are expected to be the major driving factor for growth of the global glaucoma therapeutics market. According to the International Agency for the Prevention of Blindness, 2010 data findings, it is estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of about 20 million form 2010. Furthermore, in 2010, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 11 million by 2020. The significant risk of developing glaucoma increases with geriatric population, increased intraocular pressure, positive family history for glaucoma, and ethnicity. According to the American Academy of Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040.

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%).

Glaucoma Therapeutics Market - Regional Analysis

On the basis of region, glaucoma therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in glaucoma therapeutics market, followed by Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in turn opting for glaucoma treatment are expected to drive growth of the glaucoma therapeutic market in these region. For instance, According to National Federation of the blind, 2014, an estimated 10 million people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in the U.S.

Click to Continue Reading on Glaucoma Therapeutics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Vaccine Adjuvant Market Clinical Review, Drug Descriptions, Analysis and Synthesis 2026

Adjuvant is key material that is expressed as a part of vaccine, which boost its capability to promote defense mechanism against infection. Adjuvant supports to activate immune system and permit the antigens pathogen constituents that cause an immune response in vaccines to prompt long period protective immunity. An efficient vaccine promotes both innate immunity as well as adaptive immunity, in which innate immunity is activated immediately when immune cells spots a pathogen. Successively after several days the adaptive immunity is expanded and coordinated, as immune cells called T and B cells. Adjuvants are important as they lead to immune memory which in later activate the innate immune response, subsequently leading to improved adaptive immunity with improved activation of T and B cells. According to 2015, report published by National Institute of Allergy and Infectious Disease, Alum was the only vaccine adjuvant used in U.S. till 2009, later HPV vaccine called as Cervarix was approved by Food and Drug Administration (FDA). Less immunogenicity of modern adjuvants is propelling demand for development of more efficient adjuvants in vaccines. Researchers and market players are majorly investing in R&D for development of safe and effective vaccine adjuvants, in turn boosting market growth.

To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1731

Market Dynamics

Increasing prevalence of naïve infectious chronic diseases around the globe is the major factor propelling demand for more improved and long lasting vaccination. Moreover, factors such as growing support of government in research and development, high incidences of epidemic outbreaks, tactical development interchanges adopted by companies such as acquisitions, agreements, and collaborations are supporting growth of the vaccine adjuvants market. For instance, in July 2017, the U.S Food and Drug Administration (FDA) approved Nerlynx a product of Puma Biotechnology Inc. for adjuvant treatment of breast cancer. Such innovations are driving growth of the vaccine adjuvants market. However, restrains such as side effects and high toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are expected to hinder growth of vaccine adjuvants market. For instance, an article published in 2016, Scientific Reports Journal revealed the toxicity of aluminum adjuvants in clinically approved various human vaccinations.

Regional Insights

On the basis of the region, the global vaccine adjuvant market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in market in the term of revenue, owing to high adoption of the innovative products and presence of major market players in this region especially in the U.S. Moreover, favorable government support towards the growth of healthcare infrastructure is also accelerating growth of the vaccine adjuvants market in this region. Asia Pacific region is expected to witness significant growth, owing to presence of large population prone to various chronic and infectious diseases such as HIV, influenza, hepatitis, and cancer. Therefore, introduction of innovative adjuvants vaccine may provide better solutions to the patient at the marginally lower costs. Vaccine adjuvants market is growing at significant rate, owing to development of innovative and efficient products to meet increasing demand from end users.

Click To Continue Reading on Vaccine Adjuvant Market

Market Taxonomy

On the basis of product type, the global vaccine adjuvant market is segmented into:

• Particulate Adjuvants
• Emulsions Adjuvants
• Pathogen Adjuvants
• Combination Adjuvants
• Others Adjuvants

On the basis of route of administration, the global vaccine adjuvant market is segmented into:

• Oral
• Intranasal
• Intramuscular
• Intradermal
• Others

On the basis of disease type, the global vaccine adjuvant market is segmented into:

• Cancer
• Infectious Disease
• Other

On the basis of application type, the global vaccine adjuvants market is segmented into:

• Research
• Commercial
• Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Drug Screening Market - Latest Advancements & Market Outlook 2018 to 2026

Drug Screening Market Competitive Landscape

Key players operating in the global drug screening market include Thermo Fisher Scientific, Quest Diagnostics, Omega Laboratories, Abbott Laboratories, Danaher Corporation, Express Diagnostics International Inc., Siemens Healthineers, Alfa Scientific Designs, F. Hoffmann La Roche, SureHire, and OraSure.

Drug screening involves testing of the samples such as urine, breath, oral fluid, hair, and others for presence of any substances over the limit. The significance of the drug screening is that a person under influence of the drugs or alcohol is liable for road accidents, and other workplace issues.

  

Manufacturers such as Abbott Laboratories provide drug screening tests for testing purposes at workplace, in government organizations, rehabilitation centers, and other places. These tests are painless and non-invasive. Moreover, manufacturers such as Alere, Inc. (part of Abbott Laboratories) provide point-of-care diagnostic tests for drug screening. Furthermore, drug addict individuals involved in certain professions such as an air traffic controller, and commercial drivers can risk safety of others, which can be avoided by pre-employment urine testing. On-the-job accidents could also be reduced with the help of drug screening. A urine drug test is painless and analyzes presence of prescription drugs such as amphetamines, methamphetamines, benzodiazepines, marijuana, barbiturates, cocaine, methadone, and opioids (narcotics).

Drug Screening Market Drivers

Competition among leading manufacturers in the drug screening market is supporting the growth of the drug screening market. Manufacturers are engaged in developing innovative products in wide categories in order to maintain leading position in the market. Alere, Inc. along with its partner company GenPrime, Inc., launched point of care testing device, the xReader for work-place drug testing in 2016. In 2017, Alere, Inc. launched Alere iCup Rx drug screen for detecting commonly misused and abused prescription drugs. Moreover, technological advancements are expected to boost growth of the drug screening market over the forecast period. For instance, Intelligent Fingerprinting Limited launched non-invasive portable fingerprint drug test in 2017.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1696

Drug Screening Market Insights

North America and Europe are expected to dominate the drug screening market over the forecast period due to presence of leading manufacturers such as Alere, Inc. Mergers and acquisitions by key players are expected to foster growth of the market such as Abbott Laboratories acquisition of Alere, Inc. in 2017. Asia Pacific region is expected to witness significant growth over the forecast period, owing to increasing presence of leading manufacturers in the region.

Drug Screening Market Taxonomy-

The global drug screening market is segmented on the basis of product type, application, end user, and region.

By Product Type:

·         Instruments

o   Immunoassay analyzers

o   Chromatography Instruments

o   Breathalyzers

o   Drug testing Cups

o   Dip Cards

o   Oral Fluid Testing Products

·         Consumables

By Application:

·         Urine Testing

·         Breath Testing

·         Oral Fluid Testing

·         Hair Testing

·         Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.